Dr.
Dixon: One of the things you can look at – a very sensitive
endpoint – is the percentage reduction in volume. So rather
than just response, if you look at the percentage reduction in volume
that allows you a much greater ability to detect differences between
drugs than the standard: response, no response. Because if you think
about it, you’ve got a 49% reduction partial response; if you
got 49%, you got no change. If there’s a 51%, it’s a partial
response. It’s a very artificial cut-off.
Dr.
Love: So the volume is more quantitative?
Dr.
Dixon: Yes, this is more quantitative, it is more reproducible and
you got hard copy because you got ultrasound or mammographic images
and it allows you external people to come out and review it and
say, "Well, these guys are right on this combination."
Primary
chemotherapy or hormonotherapy for patients with breast cancer.
[Review] Brain EG. Misset JL. Rouess J. Primary chemotherapy or hormonotherapy
for patients with breast cancer. [Review] Cancer Treatment Reviews.
25(4):187-97, 1999.
